Related Experiment Video

Updated: Jun 4, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

[Ipilimumab, a new molecular targetted therapy of malignant neoplastic disease]

Takahiro Mori1

  • 1Tohoku University Hospital Cancer Center, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|March 4, 2011
PubMed

Ipilimumab is a fully human monoclonal antibody that binds to CTLA-4(cytotoxic T lymphocyte-associated antigen 4). It is intended to be used as a drug to activate the immune system by binding to CTLA-4, which suppresses T-cells in natural immune responses. Recently, a phase III , multi-center, randomized, double-blind, clinical study showed an improvement in over-all/progression-free survival in patients with advanced melanomas. Ipilimumab is undergoing clinical trials for the treatment of melanoma, non-small cell lung cancer(NSCLC), small cell lung cancer(SCLC)and metastatic hormone-refractory prostate cancer, as well as other neoplastic diseases.

More Related Videos

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination05:39

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination

Published on: February 9, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...